NTEC

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharm

15-12B - Intec Pharma Ltd. (0001638381) (Filer)

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company's therapeutic focus. Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol "INDP" and a new CUSIP number (45339J 105). The previous ticker symbol was "NTEC" (NA

25-NSE - Intec Pharma Ltd. (0001638381) (Subject)

JERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ:NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with Decoy Biosystems, Inc. ("Decoy") is currently expected to close after market hours today, Tuesday, August 3, 2021, subject to satisfaction or waiver of all closing conditions. Immediately following the closing, the combined company will be renamed "Indaptus Therapeutics, Inc.", and is expected to begin trading on The Nasdaq Capital Market under the new ticker symbol "INDP" upon the commencement of trading on Wednesday, August 4, 2021. In connection with the Decoy Merger and the previously

JERUSALEM, July 26, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec Israel" or the "Company"), today announced that its wholly-owned subsidiary, Intec Parent, Inc. ("Intec US"), entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement. The private placement is being consummated to satisfy one of the closing conditions of the previously announced reverse merger with Decoy Biosystems, Inc. (the "Decoy Merger"). In connection with the Decoy Merger, Intec Israel plans to effect a 1-for-4 reverse share split of its outstanding ordinary shares for the purpose of meeting Nasdaq's initial listing re

425 - Intec Pharma Ltd. (0001638381) (Subject)

8-K - Intec Pharma Ltd. (0001638381) (Filer)

8-K - Intec Pharma Ltd. (0001638381) (Filer)

425 - Intec Pharma Ltd. (0001638381) (Subject)

425 - Intec Pharma Ltd. (0001638381) (Subject)

8-K - Intec Pharma Ltd. (0001638381) (Filer)

10-Q - Intec Pharma Ltd. (0001638381) (Filer)

EFFECT - Intec Pharma Ltd. (0001638381) (Filer)

DEFM14A - Intec Pharma Ltd. (0001638381) (Filer)

S-4/A - Intec Pharma Ltd. (0001638381) (Filer)

8-K - Intec Pharma Ltd. (0001638381) (Filer)

425 - Intec Pharma Ltd. (0001638381) (Subject)

Gainers Ocugen (NASDAQ:OCGN) stock moved upwards by 7.1% to $9.95 during Thursday's after-market session. At the close, Ocugen's trading volume reached 7.6 million shares. This is 13.18% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 billion. Soligenix (NASDAQ:SNGX) stock rose 5.79% to $1.46. Trading volume for this security closed at 35.3K, accounting for 1.06% of its average full-day volume over the last 100 days. The company's market cap stands at $58.4 million. CASI Pharmaceuticals (NASDAQ:CASI) shares rose 4.26% to $1.71. This security traded at a volume of 147 shares come close, making up 0.01% of its average volume over the las

S-4 - Intec Pharma Ltd. (0001638381) (Filer)

10-K/A - Intec Pharma Ltd. (0001638381) (Filer)

JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on Intec’s website, www.intecpharma.com, by selecting “Investors” and then “Financials” and “SEC Filings”. You may request a copy of the Company’s Form 10-K, at no cost to you, by writing to the Chief Financial Officer of the Company at 12 Hartom Street, Har Hotzvim, Jerusalem 9777512, Israel or by calling the Company at +972 (2) 586 4657. About Intec Pharma Ltd. Intec Ph

10-K - Intec Pharma Ltd. (0001638381) (Filer)

8-K - Intec Pharma Ltd. (0001638381) (Filer)

425 - Intec Pharma Ltd. (0001638381) (Subject)